Frexalimab

Frexalimab is an second-generation monoclonal antibody[1] for the treatment of relapsing multiple sclerosis, under developement by Sanofi.[2]

Frexalimab
Monoclonal antibody
TypeWhole antibody
TargetCD40 ligand
Clinical data
AHFS/Drugs.comMonograph
License data
Legal status
Legal status
  • Investigational
Identifiers
ChemSpider
  • none
KEGG

Mechanism of action

It is a CD40 ligand inhibitor.[2][1]

See also

References
  1. Media Update: Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis
  2. Media Update: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.